PO.ET03.02 · 实验与分子治疗

利用SMART-Seq® mRNA Long Read(v1和v2)试剂盒进行RNA异构体发现与定量

RNA isoform discovery and quantification with SMART-Seq® mRNA Long Read (v1 and v2) kits

海报缩略图:利用SMART-Seq® mRNA Long Read(v1和v2)试剂盒进行RNA异构体发现与定量
编号 1789 展板 9 时间 4/20 09:00–12:00 区域 Section 16 主讲 Jackson Peterson
分会场 Mechanisms of Drug Resistance 2
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Jackson Peterson1, Yue Yun1, Lisa Welter1, Kazuo Tori1, Alan Du1, Yana Ryan1, Ning Ma1, Rachana Kumar1, Shiyi Yin1, Mike Covington1, Shuwen Chen1, Elena Shagisultanova2, Mohammad Fallahi1, Bryan Bell1, Andrew Farmer1

1Takara Bio USA, Inc., San Jose, CA,2Department of Medicine/Medical Oncology, University of Colorado, Aurora, CO

摘要 Abstract

中文摘要
RNA在生物学中发挥核心作用,将基因组信息转化为效应分子,或作为功能性非编码RNA,或作为编码蛋白的mRNA。尽管人们早已认识到复杂的RNA转录本谱可通过可变剪接产生,但众多发现凸显了可变剪接在细胞和发育生物学中的重要作用。此外,异常剪接近期已被与癌症、神经退行性变和自身免疫等疾病联系起来。特别值得关注的是,癌症特异性剪接异构体已成为一种可被新型免疫治疗药物靶向的潜在新抗原来源。因此,理解RNA异构体的表达和功能在癌症生物学研究中变得日益重要。当前长读长RNA测序(LR-RNA-seq)的一个局限是需要大量的输入RNA,这对于切除的肿瘤或分选的单细胞等样本可能无法实现。在此,我们描述SMART-Seq® mRNA Long Read试剂盒,一种新型LR-RNA-seq文库制备技术,能够从单细胞(约10 pg RNA/细胞)至100 ng总RNA进行全长RNA测序。在高质量的批量RNA输入中,我们展示了以2 kb的平均读长(N50)可靠测序并检测长达8 kb全长转录本的能力,从而能够在来自健康组织和癌细胞的样本中发现并定量新型mRNA异构体。对具有进化耐受性的靶向治疗耐药癌细胞系的分析发现,差异性异构体使用与癌症治疗耐药的进化相关。我们进一步描述了该技术的升级版本SMART-Seq® mRNA Long Read version 2,它将输入范围扩展至2 μg,改善了读长性能,并支持基于UMI的分析。比较研究表明,SMART-Seq mRNA Long Read技术显著优于现有的批量和单细胞LR-RNA-seq方法。凭借一次可对多达96个样本进行PCR条形码标记,该技术将在常规长读长cDNA测序工作流程以及样本输入有限的场景中,加速科学家对剪接异构体的编目和研究。
查看英文原文 English abstract
RNA serves a central role in biology by converting genomic information into effector molecules, either as functional non-coding RNAs or as protein-coding mRNAs. While it has long been appreciated that complex RNA transcript profiles can be produced through alternative splicing, numerous discoveries have highlighted the essential role of alternative splicing in cell and developmental biology. Furthermore, aberrant splicing has recently been linked to diseases like cancer, neurodegeneration, and autoimmunity. Of particular interest, cancer-specific splice isoforms have emerged as a potential source of neo-antigens targetable by novel immune therapeutics. Thus, understanding the expression and function of RNA isoforms has become increasingly important in cancer biology research. A current limitation of long-read RNA sequencing (LR-RNA-seq) is the requirement of large amounts of input RNA, which can be unachievable for samples such as resected tumors or sorted single cells. Here, we describe SMART-Seq® mRNA Long Read kit, a new LR-RNA-seq library preparation technology that enables full-length RNA sequencing from single cells (~10 pg RNA/cell) up to 100ng total RNA. In high-quality bulk RNA inputs, we demonstrate the ability to reliably sequence at an average read length (N50) of 2 kb and to detect full-length transcripts as long as 8 kb, enabling the discovery and quantification of novel mRNA isoforms in samples from both healthy tissues and cancer cells.  Analysis of cancer cell lines with evolved resistance to targeted therapies identifies differential isoform usage associated with the evolution of cancer therapeutic resistance. We further describe an update to this technology, SMART-Seq® mRNA Long Read version 2, which expands the input range to 2µg, improves read-length performance, and enables UMI-based analysis. Comparison studies demonstrate that SMART-Seq mRNA Long Read technology substantially outperforms existing bulk and single-cell LR-RNA-seq methods. With PCR barcoding of up to 96 samples at a time, this technology will accelerate discovery as scientists catalog and study splice isoforms in both routine long read cDNA sequencing workflows and in settings where sample input is limited.
利益披露 Disclosure
J. Peterson, None.. Y. Yun, None.. L. Welter, None.. K. Tori, None.. A. Du, None.. Y. Ryan, None.. N. Ma, None.. R. Kumar, None.. S. Yin, None.. M. Covington, None.. S. Chen, None.. E. Shagisultanova, None.. M. Fallahi, None.. B. Bell, None.. A. Farmer, None.

← 返回 AACR 2026 检索